Form 4: Roivant Sciences CEO Sells Shares

Sentiment:

Insider Transaction (Form 4)


Eric Venker, President & Immunovant CEO of Roivant Sciences Ltd., sold 200,000 shares of common stock on July 27, 2026 for $34.95 per share.

Summary

  • Option exercise/conversion: acquired 200,000 Common Shares at $3.85 ($770,000) on July 27, 2026; holds 1,813,063 after (Direct).
  • Open-market sale: disposed of 200,000 Common Shares at $34.95 ($6,990,000) on July 27, 2026; holds 1,613,063 after (Direct).
  • Option exercise/conversion: disposed of 200,000 Stock Option (Right to Buy) on July 27, 2026; holds 4,044,834 after (Direct).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $6,990,000 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

Eric Venker โ€” Officer (President & Immunovant CEO)

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-07-27Option exercise/conversionCommon Shares200,000$4$770.0K1,813,063
2026-07-27Open-market saleCommon Shares200,000$35$7.0M1,613,063
2026-07-27Option exercise/conversionStock Option (Right to Buy)200,000โ€”โ€”4,044,834

Key Dates

DateDescription
2026-07-27Option exercise/conversion (200,000 shares)
2026-07-27Open-market sale (200,000 shares)
2026-07-27Option exercise/conversion (200,000 shares)

Keywords

insider transaction, Form 4, ROIV, Roivant Sciences Ltd., bearish, Eric Venker

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.